Tammy McDaid is raising £3m for her five-year-old son Tate, who has Sanfilippo Syndrome, to access a new US-approved gene therapy that is not available in the UK.
University of Michigan researchers argue that while gene editing could replace lifelong cholesterol medication, permanent genetic changes and high costs pose significant hurdles for widespread adoption.
The FDA released final guidance requiring manufacturers to implement a potency assurance strategy for cell and gene therapy products to ensure they perform as intended.